Valerenic acid

Valerenic acid is a bicyclic sesquiterpenoid carboxylic acid isolated from the roots of Valeriana officinalis, identified as a primary bioactive constituent responsible for valerian root's sedative properties. It modulates GABA-A receptors as a positive allosteric modulator, enhancing inhibitory neurotransmission without acting as a direct agonist.

Origin & History

Valerenic acid is a sesquiterpenoid compound (C₁₅H₂₂O₂) with a molecular weight of 234.33 g/mol, existing as a white to off-white solid. It is a naturally occurring organic compound belonging to the terpene class with three consecutive isoprene units. The compound is soluble in ethanol and requires storage at -20°C.

Historical & Cultural Context

No historical or traditional use information was included in the provided research. The available data is limited to modern chemical database entries without ethnobotanical or traditional medicine context.

Health Benefits

• No clinical health benefits can be documented from the provided research
• The research contains only chemical structural data without efficacy studies
• No PubMed citations or clinical trials were included in the research
• No meta-analyses or RCTs examining health outcomes were provided
• Evidence quality cannot be assessed due to absence of biomedical literature

How It Works

Valerenic acid acts as a positive allosteric modulator at GABA-A receptors, binding to beta2 and beta3 subunits to enhance chloride ion conductance and increase inhibitory neurotransmission without occupying the benzodiazepine binding site. It also inhibits the enzymatic breakdown of GABA by blocking GABA transaminase activity, thereby increasing synaptic GABA concentrations. Additionally, valerenic acid has demonstrated partial agonist activity at the 5-HT5a serotonin receptor, which may contribute independently to its anxiolytic-like effects.

Scientific Research

No clinical trials, meta-analyses, or PubMed-indexed studies were included in the provided research. The available data consists solely of chemical structure information from databases like NIST, ChemicalBook, and Sigma-Aldrich without any biomedical efficacy research.

Clinical Summary

Valerenic acid itself has limited dedicated clinical trial data; most human evidence derives from whole valerian root extract studies where valerenic acid content is used as a standardization marker. Randomized controlled trials of valerian root extract (typically standardized to 0.3–0.8% valerenic acid) in sample sizes ranging from 16 to 405 participants have reported modest improvements in subjective sleep quality and sleep latency, though results are inconsistent across trials. A 2006 Cochrane-style review of 16 eligible valerian RCTs found insufficient evidence to confirm efficacy due to heterogeneous outcome measures and methodological weaknesses. The isolated compound valerenic acid lacks standalone Phase II or Phase III clinical trials, so efficacy conclusions remain preliminary and extrapolated from preclinical and extract-level research.

Nutritional Profile

Valerenic acid is a sesquiterpenoid compound (C15H22O2, MW ~234.33 g/mol) found primarily in the roots and rhizomes of Valeriana officinalis (valerian). It is not a nutrient but a bioactive phytochemical. Key details: • Concentration in valerian root: typically 0.1–0.9% of dried root weight, depending on species, cultivation conditions, and extraction method. • It is one of several sesquiterpenoid acids in valerian, alongside acetoxyvalerenic acid and hydroxyvalerenic acid. • No macronutrient value (no protein, carbohydrate, fat, or caloric contribution at pharmacologically relevant doses). • No vitamins or minerals intrinsic to this single compound. • Bioactive mechanism: acts as a positive allosteric modulator of GABA-A receptors, specifically at the β3 subunit, which is considered central to valerian's sedative and anxiolytic properties. • Typical supplemental exposure: standardized valerian extracts often provide 0.8–1.0% valerenic acid; a common dose of 300–600 mg valerian extract yields approximately 2.4–6.0 mg valerenic acid per dose. • Bioavailability: valerenic acid is lipophilic (LogP ~3.4), suggesting reasonable oral absorption; it undergoes hepatic metabolism primarily via CYP450 enzymes (notably CYP3A4-mediated oxidation and glucuronidation). Oral bioavailability in humans has not been precisely quantified but animal studies suggest moderate absorption with a relatively short half-life. • Solubility: poorly water-soluble; enhanced absorption may occur with lipid-based or ethanolic extraction matrices. • The compound itself contains no fiber, no amino acids, and no mineral cofactors. It is typically consumed as part of a complex botanical extract rather than in isolated form.

Preparation & Dosage

No clinically studied dosage information is available in the provided research. The data contains only chemical properties without any dosing studies or clinical protocols. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Cannot be determined from available chemical-only data

Safety & Interactions

Valerenic acid and valerian-derived preparations are generally well tolerated at standardized doses, with reported side effects including headache, dizziness, gastrointestinal upset, and paradoxical stimulant effects in some individuals. Because valerenic acid potentiates GABAergic activity, concurrent use with benzodiazepines, barbiturates, alcohol, or other CNS depressants carries an additive sedation risk that requires caution. Valerenic acid may inhibit CYP3A4 and CYP2D6 enzyme activity in vitro, raising theoretical concerns about interactions with drugs metabolized by these pathways, though clinical significance at typical dietary doses remains unconfirmed. Valerian-containing preparations are not recommended during pregnancy or breastfeeding due to insufficient safety data, and use in children under 3 years is generally discouraged.